ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

28 links11 made here, not in the record48 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule basedReplaced, or read an older versionMade here
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06145308Precision Treatment ofRecurrent/MetastaticSalivary Gland CarcinomaGuided by Molecular TypingPeking Union Medical CollegePhase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSSalivary Gland NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSTyrosine kinase inhibitors …Entry “TKI”, read by our name rule›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAlbumin-Bound PaclitaxelEntry “albumin-bound paclitaxel+trast…›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundTrastuzumabEntry “albumin-bound paclitaxel+trast…›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundPyrotinibEntry “albumin-bound paclitaxel+trast…›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundINT008936Entry “AR,AR antagonist ++ goserelin …›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedGoserelinEntry “AR,AR antagonist ++ goserelin …›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPertuzumabEntry “AR,AR antagonist ++ goserelin …›Nov 3 · Claude Opus 5.5 · BackgroundNov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundDocetaxelEntry “AR,AR antagonist +goserelin +d…›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedIparomlimabEntry “iparomlimab + tuvonralimab”, r…›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTuvonralimabEntry “iparomlimab + tuvonralimab”, r…›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCadonilimabIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAlpelisibEntry “alpelisib+fulvestrant”, read b…›Nov 3 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · TestedBackground · optionFulvestrantEntry “alpelisib+fulvestrant”, read b…›Nov 3 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · TestedBackground · optionPARP inhibitorsEntry “PARP inhibitor”, read by our n…›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedEnfortumab vedotinIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedINT010594Entry “HER2, pyrotinib + pertuzumab/t…›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundPembrolizumabMade here · Found by reading; no entr…›Nov 1 · Claude Opus 5.5 · BackgroundBackgroundLenvatinibMade here · Found by reading; no entr…›Nov 2 · Claude Opus 5.5 · BackgroundBackgroundOlaparibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · TestedTestedNiraparibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · TestedTestedTrastuzumab deruxtecanMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · TestedTestedPalbociclibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · TestedTestedAbemaciclibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · Background · optionBackground · optionSacituzumab govitecanMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · Background · optionBackground · optionAnastrozoleMade here · Found by reading; no entr…›Nov 10 · Claude Opus 5.5 · Background · optionBackground · optionExemestaneMade here · Found by reading; no entr…›Nov 10 · Claude Opus 5.5 · Background · optionBackground · optionEntrectinibMade here · Found by reading; no entr…›Nov 10 · Claude Opus 5.5 · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Tyrosine kinase inhibitors (TKIs)

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “TKI”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 1Pembrolizumabmade hereClaude Opus 5.5BackgroundCurrent
Nov 2Lenvatinibmade hereClaude Opus 5.5BackgroundCurrent
Nov 3Tyrosine kinase inhibitors (TKIs)Claude Opus 5.5TestedCurrent
Nov 3Albumin-Bound PaclitaxelClaude Opus 5.5BackgroundCurrent
Nov 3TrastuzumabClaude Opus 5.5BackgroundCurrent
Nov 3PyrotinibClaude Opus 5.5BackgroundCurrent
Nov 3INT008936Claude Opus 5.5TestedCurrent
Nov 3GoserelinClaude Opus 5.5TestedCurrent
Nov 3PertuzumabClaude Opus 5.5BackgroundReplaced
Nov 3DocetaxelClaude Opus 5.5TestedCurrent
Nov 3IparomlimabClaude Opus 5.5TestedCurrent
Nov 3TuvonralimabClaude Opus 5.5TestedCurrent
Nov 3CadonilimabClaude Opus 5.5TestedCurrent
Nov 3AlpelisibClaude Opus 5.5TestedReplaced
Nov 3FulvestrantClaude Opus 5.5TestedReplaced
Nov 3PARP inhibitorsClaude Opus 5.5TestedCurrent
Nov 3Enfortumab vedotinClaude Opus 5.5TestedReplaced
Nov 3INT010594Claude Opus 5.5BackgroundCurrent
Nov 3Olaparibmade hereClaude Opus 5.5TestedCurrent
Nov 3PertuzumabClaude Opus 5.5BackgroundCurrent
Nov 3Niraparibmade hereClaude Opus 5.5TestedCurrent
Nov 3Trastuzumab deruxtecanmade hereClaude Opus 5.5TestedCurrent
Nov 3Palbociclibmade hereClaude Opus 5.5TestedCurrent
Nov 3Abemaciclibmade hereClaude Opus 5.5Background · optionCurrent
Nov 3AlpelisibClaude Opus 5.5Background · optionCurrent
Nov 3FulvestrantClaude Opus 5.5Background · optionCurrent
Nov 3Sacituzumab govitecanmade hereClaude Opus 5.5Background · optionCurrent
Nov 10Enfortumab vedotinClaude Opus 5.5TestedCurrent
Nov 10Anastrozolemade hereClaude Opus 5.5Background · optionCurrent
Nov 10Exemestanemade hereClaude Opus 5.5Background · optionCurrent
Nov 10Entrectinibmade hereClaude Opus 5.5TestedCurrent
Nov 18Tyrosine kinase inhibitors (TKIs)Rule based · role ruleTestedAgrees
Nov 18Albumin-Bound PaclitaxelRule based · role ruleTestedOverridden
Nov 18TrastuzumabRule based · role ruleTestedOverridden
Nov 18PyrotinibRule based · role ruleTestedOverridden
Nov 18INT008936Rule based · role ruleTestedOverridden
Nov 18GoserelinRule based · role ruleTestedOverridden
Nov 18PertuzumabRule based · role ruleTestedOverridden
Nov 18DocetaxelRule based · role ruleTestedAgrees
Nov 18IparomlimabRule based · role ruleTestedAgrees
Nov 18TuvonralimabRule based · role ruleTestedAgrees
Nov 18CadonilimabRule based · role ruleTestedAgrees
Nov 18AlpelisibRule based · role ruleTestedOverridden
Nov 18FulvestrantRule based · role ruleTestedOverridden
Nov 18PARP inhibitorsRule based · role ruleTestedAgrees
Nov 18Enfortumab vedotinRule based · role ruleTestedAgrees
Nov 18INT010594Rule based · role ruleTestedOverridden
As of nowSalivary Gland NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.